Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
Natalizumab Use In Multiple Sclerosis: A Real World Evidence (Rwe) Analysis of Its Impact on Nhs Resources In England.
Increased serum levels of C21 steroids in female patients with multiple sclerosis.
Preliminary Evidence of Increased Hippocampal Myelin Content in Veterans with Posttraumatic Stress Disorder.
What lies beneath grey matter atrophy in multiple sclerosis?
Restriction genes for retroviruses influence the risk of multiple sclerosis.
Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: Experience from the Mangalore demyelinating disease registry.
Longitudinally extensive transverse myelitis associated with dengue fever.
Causes and Consequences of MicroRNA Dysregulation in Neurodegenerative Diseases.
Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.
Susceptibility Genes for Multiple Sclerosis Identified in a Gene-Based Genome-Wide Association Study.
Sphingosine-1-Phosphate Receptor Antagonism Enhances Proliferation and Migration of Engrafted Neural Progenitor Cells in a Model of Viral-Induced Demyelination.
FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
Pre-Existing Mature Oligodendrocytes Do Not Contribute to Remyelination following Toxin-Induced Spinal Cord Demyelination.
Multiple sclerosis influences the precision of the ankle plantarflexon muscular force production.
Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
Ultrasound of inherited vs. acquired demyelinating polyneuropathies.
[Pathology and definition of multiple sclerosis].
Using A Mixed Methods Approach to Develop A Discrete Choice Experiment In Multiple Sclerosis.
Disease-modifying treatments for multiple sclerosis - a review of approved medications.
An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis.
Alterations in tight junction protein and IgG permeability accompany leukocyte extravasation across the choroid plexus during neuroinflammation.
Magnetization transfer ratio recovery in new lesions decreases during adolescence in pediatric-onset multiple sclerosis patients.
The impact of microglial activation on blood-brain barrier in brain diseases.
Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis.
Pages
« first
‹ previous
…
693
694
695
696
697
698
699
700
701
…
next ›
last »